Oncology Clinical Trials in New Haven, CT
As of September 2026, 212 paid clinical trials are recruiting for Oncology in New Haven, Connecticut. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in New Haven
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Unified Network for Integrated Fluid Collection at Yale
214 clinical trials for Oncology
·Clear filters·A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A Study of ASP3082 in Adults With Advanced Solid Tumors
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Top Research Study Locations in New Haven
Researchers run research studies in New Haven, CT at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Yale University | Acute Myeloid Leukemia, Alcohol Use Disorder, Stage IV Lung Cancer AJCC v8 | 247 |
| Yale Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, NSCLC | 67 |
| Yale New Haven Hospital | Ischemic Stroke, Multiple Myeloma, NAFLD | 63 |
| Yale University School of Medicine | Alzheimers Disease, Alzheimers Disease, Familial, Colorectal Cancer | 58 |
| Yale School of Medicine | Epilepsy, Epilepsy (Treatment Refractory), Hemoglobinopathies | 41 |
| Smilow Cancer Center/Yale-New Haven Hospital | Ovarian Carcinoma, Plasma Cell Myeloma, Advanced Hepatocellular Carcinoma | 20 |
| Yale | AML, MDS, Acute Gastrointestinal Bleeding | 12 |
| Yale-New Haven Hospital | Acute Ischemic Stroke, Acute Myeloid Leukemia, Anemia, Sickle Cell | 12 |
| Connecticut Mental Health Center | Borderline Personality Disorder, Alcohol Use, Alcohol Use Disorder | 11 |
| GSK Investigational Site | HIV Infections, Colonic Neoplasms, Gastrointestinal Neoplasms | 8 |
| Smilow Cancer Hospital at Yale New Haven | Advanced Solid Tumor, AML, AML With Mutated NPM1 | 8 |
| Yale Child Study Center | Speech, Anxiety Disorder of Adolescence, Autism | 7 |
| Yale New Haven Health | Chronic Kidney Diseases, Claudication, Critical Limb Ischemia | 7 |
| Musical Intervention Studios | COVID-19, Mental Health Issue, Alzheimer Disease | 6 |
| Smilow Cancer Hospital | Cancer, Sickle Cell Disease, Glioma, Malignant | 6 |
| Yale New Haven Health System | Aortic Stenosis, Heart Failure, ATTR Amyloidosis With Cardiomyopathy | 6 |
| Yale University School Of Medicine | Colorectal Neoplasms, Healthy Volunteers, Irritability Associated With Autism Spectrum Disorder | 6 |
| Yale University, Yale Cancer Center | Breast Cancer, Endometrial Cancer, Ovarian Cancer | 6 |
| BLOOM | COVID-19, Mental Health Issue | 5 |
| Clinical Trial Site | Breast Cancer, ER Positive Breast Cancer, Generalized Myasthenia Gravis | 5 |
| Smilow Cancer Hospital - Yale New Haven Health | Breast Cancer, Esophageal Cancer, Advanced Non-Small Cell Lung Cancer | 5 |
| Yale University Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, Anal Squamous Cell Carcinoma | 5 |
| Yale New Haven Children's Hospital | Antibiotic Stewardship, Failed or Difficult Intubation, Sequela, Intubation Complication | 4 |
| Yale University Yale Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, B Cell Lymphoma | 4 |
| Yale-New Haven Hospital-Yale Cancer Center | Advanced Breast Cancer, Breast Cancer, CRC | 4 |
Active & Upcoming Studies in New Haven (2026)
Recruiting trials in New Haven grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (313 active studies)
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma · Phase 2 · National Cancer Institute (NCI)
- Unified Network for Integrated Fluid Collection at Yale · Yale University
Neurology & pain (46 active studies)
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" · Phase 3 · Yale University
- Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain · Phase 2 · Yale University
Cardiovascular (39 active studies)
- Health-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For Health · Yale University
- Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants · University of Alabama at Birmingham
Diabetes & metabolic (36 active studies)
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes · Phase 1 · Yale University
- Glucose, Understanding, Integrated Digital Health, and Engagement (GUIDE) Study · Yale University
Mental health & behavior (26 active studies)
- Real-time Opioid Study · Yale University
- The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease · Phase 2 · Yale University
Vaccines (11 active studies)
HIV / STI (11 active studies)
- A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed · Phase 3 · ViiV Healthcare
- RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry · University of Texas Southwestern Medical Center
Pediatric (6 active studies)
Common conditions studied in New Haven
- Advanced Solid Tumor (22 active studies)
- Breast Cancer (20 active studies)
- Alcohol Use Disorder (16 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Advanced Solid Tumors (12 active studies)
- Heart Failure (11 active studies)
Leading research sponsors in New Haven
- Yale University
- National Cancer Institute (NCI)
- Children's Oncology Group
- SWOG Cancer Research Network
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in New Haven?
There are approximately 851 recruiting clinical trials in New Haven, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Haven pay participants?
Most recruiting trials in New Haven compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Haven?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Haven?
The most common conditions under active study in New Haven include Advanced Solid Tumor (22), Breast Cancer (20), Alcohol Use Disorder (16), Acute Myeloid Leukemia (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Haven?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Haven on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Haven?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Haven?
Recruiting research sites in New Haven include Yale University, Yale Cancer Center, Yale New Haven Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Haven right now?
The largest active categories in New Haven are Cancer & tumors (313), Neurology & pain (46), Cardiovascular (39). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.